(CBN Global) March 25 -- The pharmaceutical industry's revenue growth rate fell to nine percent last year from 11 percent a year earlier. Yet, in the A-shares market, bio-pharmaceutical companies continue to lead growth in the pharmaceutical sector, CBN has learned from published company annual reports.
A number of bio-pharmaceutical companies doubled their earnings through continued mergers and acquisitions. Shanghai RAAS Blood Products Co. [SHE:002252] reported a net profit of CNY1.442 billion (USD221.4 million) last year, an increase of 182.27 percent year-on-year. Harbin Pharmaceutical Group Co. [SHA:600664] generated a net profit of CNY580 million, up 134.77 percent year-on-year.
The overall fast growth in the biological medical product industry has attracted investors. Private equity funds rank among the top ten shareholders in more than 20 such listed companies. Private equity firms invested in over ten bio-pharmaceutical companies in the fourth quarter of last year.
"The combination of high technology, high levels of investment, high risk, high yield and a long cycle have positioned the biomedicine industry as a key area for long-term investment opportunities," Mr. Huang Qing, executive partner of private equity firm Shenzhen GTJA Investment Group Co., told CBN.
Biotech medicines took the top ten places among best-selling drugs worldwide in 2015, statistics show.